Atossa Therapeutics, Inc.
ATOS
$1.88
$0.116.22%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -37.64M | -34.77M | -30.18M | -28.72M | -26.34M |
| Total Depreciation and Amortization | 16.00K | 16.00K | 16.00K | 16.00K | 16.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.81M | 2.65M | 2.92M | 4.60M | 4.15M |
| Change in Net Operating Assets | 1.44M | 2.35M | 969.00K | -912.00K | -116.00K |
| Cash from Operations | -33.38M | -29.76M | -26.27M | -25.02M | -22.29M |
| Capital Expenditure | -14.00K | -23.00K | -16.00K | -19.00K | -22.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -14.00K | -23.00K | -16.00K | -19.00K | -22.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | 3.37M | 3.37M | 3.47M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | 3.37M | 3.37M | 3.47M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -33.40M | -29.79M | -22.92M | -21.67M | -18.84M |